IDEXX Laboratories, Inc. announced the promotion of Michael Erickson, PhD, to President and Chief Executive Officer, succeeding Jay Mazelsky.
Mazelsky will transition to the role of Executive Chair of the Board of Directors.
Dr. Erickson, with nearly two decades of leadership experience in healthcare technology and innovation, will join the Board upon assuming the role of President and CEO.
Effective May 12, 2026, Michael Erickson, PhD, will become the new President and CEO of IDEXX Laboratories, Inc.
Current CEO, Jay Mazelsky, will move to the role of Executive Chair and retire from the Company after the annual meeting in May 2027.
Dr. Erickson will join IDEXX's Board upon assuming the position of President and CEO.
CEO Succession
The appointment of Dr. Erickson as President and CEO of IDEXX Laboratories, Inc., effective May 12, 2026, marks a pivotal moment in the company's leadership transition.
Transition Plan
Jay Mazelsky's shift to Executive Chair and subsequent retirement after the May 2027 annual meeting ensures a structured and seamless transfer of responsibilities within IDEXX.
Board Addition
Dr. Erickson's inclusion into IDEXX's Board upon taking up the mantle of President and CEO enhances the strategic guidance and expertise available to the company.
- The elevation of Dr. Erickson to the role of President and CEO reflects IDEXX's deliberate move towards ensuring continuity and fostering growth within the veterinary diagnostics sector.
- Jay Mazelsky's transition to Executive Chair underscores IDEXX's dedication to a well-thought-out succession strategy, promoting stability and sustained performance.
IDEXX Laboratories, Inc. is poised to embark on a new era with Dr. Michael Erickson leading as President and CEO, supported by Jay Mazelsky in the role of Executive Chair. The company's emphasis on innovation and seamless leadership transition positions it for continued success in the veterinary healthcare industry.